Tissue plasminogen activators (tPAs) are accepted agents for the therapy of selected cases of acute ischaemic cerebrovascular events, such as myocardial infarction, pulmonary embolism, portal vein thrombosis, and deep venous thrombosis [1, 2]. This evidence concerns the gene PLAT and myocardial infarction.